1. Lactobacillus acidophilus supplementation in human subjects and their resistance to enterotoxigenic Escherichia coli infection.
- Author
-
Ouwehand AC, ten Bruggencate SJ, Schonewille AJ, Alhoniemi E, Forssten SD, and Bovee-Oudenhoven IM
- Subjects
- Abdominal Pain etiology, Abdominal Pain prevention & control, Adult, Diarrhea etiology, Diarrhea prevention & control, Double-Blind Method, Escherichia coli Infections immunology, Escherichia coli Infections microbiology, Escherichia coli Infections physiopathology, Escherichia coli Vaccines adverse effects, Escherichia coli Vaccines immunology, Feces chemistry, Feces microbiology, Foodborne Diseases immunology, Foodborne Diseases microbiology, Foodborne Diseases physiopathology, Gastroenteritis immunology, Gastroenteritis microbiology, Gastroenteritis physiopathology, Humans, Immunoglobulin A analysis, Immunoglobulin M analysis, Leukocyte L1 Antigen Complex analysis, Male, Probiotics adverse effects, Severity of Illness Index, Vaccines, Attenuated adverse effects, Vaccines, Attenuated immunology, Young Adult, Disease Resistance, Enterotoxigenic Escherichia coli immunology, Escherichia coli Infections prevention & control, Foodborne Diseases prevention & control, Gastroenteritis prevention & control, Lactobacillus acidophilus immunology, Probiotics therapeutic use
- Abstract
To assess the effect of Lactobacillus acidophilus (American Type Culture Collection (ATCC) 700396) on enterotoxigenic Escherichia coli (ETEC) infection, in the present study, a parallel, double-blind, placebo-controlled 4-week intervention was performed in healthy males. The subjects largely consumed their habitual diet, but had to abstain from consuming dairy foods generally high in Ca. The subjects were randomised into the L. acidophilus (dose 10⁹ colony-forming units twice daily; n 20) or the placebo (n 19) group. After an adaptation period of 2 weeks, the subjects were orally infected with a live, but attenuated, ETEC vaccine, able to induce mild, short-lived symptoms. Before and after the challenge, the subjects recorded stool consistency, bowel habits, and frequency and severity of gastrointestinal complaints. The ETEC challenge led to a significant increase in faecal output on the 2nd day and a concomitant increase in Bristol stool scale scores. Likewise, abdominal pain, bloating, flatulence, fever, headache and nausea peaked 1 d after the oral challenge. The concentrations of faecal calprotectin and IgA peaked 2 d after and that of serum IgM peaked 9 and 15 d after the oral challenge. The concentrations of serum IgA and IgG were unaffected. The ETEC challenge led to a reduction in the number of Bacteroides-Prevotella, Bifidobacterium, Clostridium cluster XIVab and total faecal bacteria. Probiotic treatment was associated with a larger increase in Bristol stool scale scores and more fever, headache and nausea after the ETEC challenge compared with the placebo treatment. These differences were, however, small and with substantial variation within the groups. Oral application of an attenuated live ETEC vaccine provides a useful model for food-borne infections. Supplementation with L. acidophilus ATCC 700396, however, was ineffective in reducing ETEC infection symptoms in healthy men.
- Published
- 2014
- Full Text
- View/download PDF